ETFs Are Net Sellers of AbbVie (ABBV) on Nov. 18
This article first appeared on GuruFocus.
ETFs sold $124.5 million in AbbVie (ABBV) shares on Wednesday, Nov. 18, by net dollar value. More funds traded the other way, however: 32 ETFs bought the stock versus 25 that sold, but the sellers moved larger amounts. The net selling ended a three-day run of net buying, which totaled $11.4 million on Nov. 17 and $47.3 million in each of the two prior sessions. ETF activity on the day also included 157 funds holding their positions unchanged.
See which funds are buying and selling on GuruFocus ETF Trends, or find and compare funds with the ETF Screener.
Every ETF and guru trade in ABBV is tracked on the ABBV guru trades page.
Which ETFs sold ABBV on Wednesday?
The largest sellers by dollar value were SPY ($93.2 million), XLV ($25.9 million) and IYH ($8.0 million). In all, 32 ETFs added shares and 25 cut them.
SPY accounted for the largest share of the move, shedding 325,699 shares worth $93.2 million, a 1.49% cut to its stake and 0.8% of its portfolio. XLV followed with a $25.9 million reduction, or 90,391 shares, trimming its position by 0.7% at a 7.71% weight. IYH sold $8.0 million, SPXL $1.6 million, and CGUS and JAVA $1.1 million each. AbbVie, a Healthcare company in the Drug Manufacturers – General industry, carries a market cap of $501.2 billion.
Have ETFs been buying or selling ABBV lately?
Over the last 5 reported days, ETFs were net buyers on 3 and net sellers on 2, so the recent trend is mostly buying.
What does ABBV do?
AbbVie is a global, diversified research-based biopharmaceutical company that operates as a single segment dedicated to discovering, developing, manufacturing, and commercializing innovative medicines.
AbbVie reported $66.01 billion in trailing 12-month revenue, up 10.6% over one year, with gross margin of 73.7% and net margin of 15.7%. The stock trades at a P/E of 48.8 and a P/S of 7.61 against a $501.2 billion market cap. Its GF Score is 76, and at $283.54 the price sits above the GF Value of $229.98. The dividend yield is 2.32%, and the shares have returned 27.81% year to date.